Linz, Valerie Catherine http://orcid.org/0000-0002-8018-5484
Schwanbeck, Carina
Krajnak, Slavomir
Anic, Katharina
Jäkel, Jörg
Schwab, Roxana
Schmidt, Marcus
Schmidberger, Heinz
Hasenburg, Annette
Battista, Marco Johannes
Funding for this research was provided by:
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Article History
Received: 6 February 2022
Accepted: 1 April 2022
First Online: 22 April 2022
Declarations
:
: V.C.L., C.S., J.J., H.S. and M.J.B. have no relevant financial or non-financial interests to disclose. M.S. reports personal fees from AstraZeneca, BioNTech, Daiichi Sankyo, Eisai, Lilly, MSD, Novartis, Pantarhei Bioscience, Pfizer, Roche, and SeaGen outside the submitted work. Institutional research funding from AstraZeneca, BioNTech, Eisai, Genentech, German Breast Group, Novartis, Palleos, Pantarhei Bioscience, Pierre Fabre, and SeaGen. In addition, M.S. has a patent for EP 2390370 B1 issued and a patent for EP 2951317 B1issued. SK received speaker honoraria from Roche Pharma AG and Novartis Pharma GmbH Germany, research funding from Novartis Pharma GmbH Germany and travel reimbursement from PharmaMar and Novartis Pharma GmbH Germany. A.H. reports honoraria from AstraZeneca, Celgen, MedConcept GmbH, Med update GmbH, Medicultus, Pfizer, Roche Pharma AG, Streamedup!GmbH, Tesaro Bio Germany GmbH, LEO Pharma, Clovis Oncology. A.H. is ad board for PharmaMar, Roche Pharma AG, Tesaro Bio Germany GmbH, AstraZeneca, LEO Pharma, GSK/MSD. R.S. received honoraria from Roche Pharma AG, AstraZeneca, Streamedup!GmbH. K.A. received honoraria from Clovis Oncology and Roche.
: This is an observational study and no ethical approval is required. The retrospective cohort study was conducted in accordance with the “Ethical principles for medical research involving human subjects” of the current version of the Declaration of Helsinki. Data collected for this study were obtained as part of routine medical care.